Hodgkin lymphoma - Clinical

Overview of Presentations with access to videos on demand (EHA subscription needed)


The study authors conclude that after 60.9 months’ median follow-up, robust and durable treatment benefits improvements that were independent of disease stage, risk factor score, and PET2 status were seen with brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A+AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). Treatment adaptation by interim PET2 status was not required for A+AVD and bleomycin exposure was avoided. Treatment with A+AVD provides sustained progression-free survival benefits and a manageable safety profile with symptoms of peripheral neuropathy improving or resolving over time and similar pregnancy rates in both treatment arms, suggesting that A+AVD is an attractive treatment option for all patients with previously untreated Stage III or IV cHL.


The study authors conclude that with extended follow-up, camrelizumab monotherapy continues to provide a robust and durable response, long progression-free and overall survival, as well as manageable safety in patients with r/r cHL.


The study authors conclude that long-term follow-up data from patients with R/R cHL treated with tislelizumab further demonstrated the substantial therapeutic activity and continued progression-free survival benefit. There were no new safety concerns identified for long-term treatment with tislelizumab.


The study authors conclude that in this first radiomics analysis in a large cohort of r/r cHL patients, combining radiomics and clinical features results in a strong prediction model for 3-year time to progression with a tAUC of 0.90, CV-AUC of 0.79, and a vAUC of 0.77 in an independent validation cohort. The model uses robust PET features that address inter-lesional heterogeneity in distance, metabolic volume, and SUV. Therefore, this model is suitable for application in clinical trials and could guide risk-stratified treatment in r/r cHL.


The study authors conclude that the present follow-up analysis of a randomized phase II study evaluating the BrECADD and BrECAPP protocols in newly diagnosed advanced cHL confirmed the high efficacy of these regimens. There were no new safety signals. The BrECADD protocol currently challenges standard eBEACOPP in the randomized GHSG phase III HD21 study.